Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Ascending Doses of Surotomycin in Healthy Volunteers
NCT02835105Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2009
- Primary completion
- Mar 2009
- Modality
- Cyclic Peptides, Peptide Conjugates, Antimicrobial Peptides
01
Overview
Phase 1, randomised, double-blind trial of surotomycin in Clostridioides difficile infection (CDI) (5 arms), sponsored by Merck & Co. Primary endpoints: Number of participants with an Adverse Event and Number of participants who discontinued study due to an AE. Started Jan 2009; status: completed.
02
Drugs
surotomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02835105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835105.